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A B S T R A C T   
Metabolism is a tightly regulated sequence of events, supported by key reactions between enzymes and enzyme- 
specific substrates. These reactions have the potential to produce metabolic side products that can have dele-
terious effects to further key metabolic reactions. The nicotinamide repair system consists of two partner en-
zymes, NAD(P)HX epimerase (NAXE) and NAD(P)HX dehydratase (NAXD). These enzymes regulate the levels of 
metabolic side products. Here we present a case of an 11-month old child who presented to our paediatric 
department with pyrexia, lethargy and multiple cutaneous lesions on the background of NAXD deficiency, a 
lethal neurometabolic disorder of early childhood. Despite early intervention with intravenous antibiotics, the 
patient failed to improve and subsequently passed away. The skin lesions were thought to be a consequence of 
systemic disease rather than a propagator of infection. Clinicians should be aware of this incredibly rare 
metabolic disease, its potential to cause widespread systemic dysfunction and the developing avenues for 
management.   
1. Introduction 
This case report adheres to the 2018 SCARE guidelines [1]. 
Metabolism is a tightly regulated sequence of events, supported by 
key reactions between enzymes and enzyme-specific substrates [2]. 
These reactions have the potential to produce metabolic side products, 
the accumulation of which can have potential deleterious effects to 
further key metabolic reactions. In 2013, Linster et al. [3] identified a 
number of enzymes forming integral metabolite repair systems in all 
domains of life. 
Nicotinamide adenine dinucleotides (NAD) (reduced from NADH 
oxidised from NAD+) and nicotinamide adenine dinucleotide phosphate 
(NADP) (reduced from NADPH and oxidised from NADP+) have 
essential roles in a series of catabolic reactions, mitochondrial energy 
production and antioxidant protection systems [4,5]. NAD and NADP 
are prone to hydration, forming inactive cofactors NADHX and 
NADPHX, respectively [6]. This can occur spontaneously but may also 
be enzyme mediated. 
Physical stress, infection or pyrexia also have the potential to pro-
duce NADPHX, a metabolite with the ability to inhibit biosynthesis 
pathways [6]. Its accumulation is toxic to cells, requiring a metabolite 
repair system to aid detoxification. The nicotinamide repair system is 
coordinated by two cofactor enzymes, NAD(P)HX epimerase (NAXE) 
and NAD(P)HX dehydratase (NAXD). NAXE converts R-NADPHX to 
S-NADPHX and NAXD which converts S-NADPHX back to NADPH in an 
ATP-dependant manner. NAXE and NAXD have a ubiquitous tissue 
distribution and are expressed across multiple species, suggesting they 
are a critical in sustaining life [7,8]. The literature reports a handful of 
cases in which a deficiency of this cofactor system has led to the 
development of significant multi-system dysfunction, such as rapid 
neurological deterioration, seizures, respiratory insufficiency and heart 
failure. Although the devastating effects on the brain and heart are well 
described, cutaneous manifestations are less widely reported [2,9,10]. 
Here we present a case of a child with NAXD deficiency, referred to our 
department with multiple cutaneous lesions on his back, axilla and 
nappy area. This case report aims to highlight the cutaneous manifes-
tations of NAXD deficiency and stress the importance of early manage-
ment of infection in patients with a background of this metabolic 
disorder. 
2. Presentation of case 
Baby X is a 11 month-old baby who presented to our paediatric 
department via ambulance with fevers, lethargy and loose stools. He had 
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a past medical history of developmental delay, infantile spasms and 
seizures on the background NAXD deficiency. There was no family 
history of any metabolic disorders. The patient was pyrexial and 
leukopenic on admission (Fig. 1). He had been off his feeds and had a 
change in bowel habit for almost 2 weeks with an increasing frequency 
of spasms and seizures.                     
On admission, multiple skin lesions were noted, starting on the nape 
of the neck and progressing to the posterior aspect of the trunk, both 
axilla and nappy area (Fig. 2). These were confluent areas of epidermal 
loss and blistering. The clinical appearance was very similar to that of a 
superficial partial thickness burn covering approximately 5% TBSA and 
hence the patient was referred for Burns Centre Specialist review. 
These were originally thought to be the potential cause of the pa-
tient’s deterioration. The patient was treated for sepsis secondary to 
cellulitis, receiving intravenous broad-spectrum antibiotics including 
ceftriaxone 560mg once-daily and co-amoxiclav 210mg eight hourly 
(dose-adjusted for weight). It was later thought that these skin lesions 
were a consequence of systemic disease rather than the propagator of 
infection. These lesions were managed conservatively with a non- 
adhesive silicone-based dressing (Silflex©). Other options included 
simple paraffin, to which the patient was allergic. 
The patient was thoroughly investigated for other potential sources 
of infection, including blood cultures, urinalysis, wound swabs, CT and 
MRI imaging of the brain. Urinalysis revealed a Klebsiella urinary tract 
infection. The patients’ antibiotic therapy was subsequently rationalised 
to cefalexin 175mg four times a day. Despite ongoing treatment, the 
combination of infection on the background of NAXD deficiency resul-
ted in irreversible neurological damage. The patient failed to improve 
and subsequently passed away. 
3. Discussion 
NAXD deficiency is an incredibly rare mitochondrial disease that 
presents in early childhood, with only 18 cases recognised in the liter-
ature to date [2,10]. In this article, we present a rare case of systemic 
deterioration in a child with NAXD deficiency secondary to a Klebsiella 
urinary tract infection. 
NAXD and NAXE are critical in the repair of toxic metabolites 
generated from NAD and NAPD, which have the potential to impede 
normal metabolic reactions critical to normal cellular function and 
overall health in humans. These disturbances occur through the 
inhibition of key cellular enzymes, including various mitochondrial 
dehydrogenases [2]. 
In 2019, Van Berger et al. [2] presented a series of individuals 
affected by homozygous and compound heterozygous NAXD mutations. 
As in this case, they observed multi-system disease and skin lesions 
induced by febrile illness. They report that the distribution of these le-
sions were similarly associated with areas of relatively high surface 
temperature, such as flexural creases (axillar and groin) and posterior 
neck [2,10]. Other notable clinical features associated with these epi-
sodes, include developmental regression and early onset neuro-
degeneration [2]. Earlier studies performed by Kremer et al. [9], using 
exome sequencing, identified biallelic pathogenic mutations in NAXE in 
children from four families suffering from sub-acute early-onset ataxia, 
cerebellar oedema, spinal myopathy and skin lesions. Like NAXD defi-
ciency, these symptoms were precipitated and exasperated by fevers, 
ultimately leading to death in the early years of life [2,9]. 
NAXE levels in fibroblasts isolated from all four individuals were 
undetectable, with high concentrations of cyclic-NADHX produced from 
the degradation of NAD(P)HX, confirming deficiency of the NAD(P)HX 
cofactor system [9]. Fibroblasts harvested from patients with missense 
NAXD mutations also express greater levels of toxic co-factors, 
S-NADHX, R-NADHX and their derivative cyclic-NADHX, compared to 
the control. Furthermore, growth rates of fibroblasts harvested from 
individuals with NAXD deficiency showed significant decreased growth 
rates, when compared to control samples [1]. Both NAXD and NAXE 
deficient fibroblast populations demonstrate significantly reduced 
thermostability compared to the controls [2,7,9]. This, alongside 
increased spontaneous hydration of co-factors NADH and NADPH at 
increased temperatures and under acidic conditions provides some 
explanation as to why fever or infection can have such a detrimental 
effect [11,12]. These effects are more pronounced in the brain, where 
there is a sustained high energy demand and so, accumulation of toxic 
NAD(P)HX has particularly deleterious effects through disturbances in 
mitochondrial energy production [2]. The cutaneous effects of toxic 
cofactors appear to lead the disruption of the dermal-epidermal junction 
and this was confirmed by skin biopsies in previous reports, which 
showed detachment of epidermis from dermis with lymphocytes around 
vessels in the upper dermis [10]. We postulate that the cause of this may 
be due to local accumulation of toxic cofactors due to high surface 
temperature. Patients who present with pyrexia on the background of 
NAXD deficiency can be challenging to manage. It is important to 
recognise that infection can propagate multisystem dysfunction in pa-
tients with this metabolic disorder, requiring clinical input from various 
specialties. A multidisciplinary approach is necessary to provide 
appropriate support and management of vital organ systems. 
Vitamin B3 (nicotinamide) therapy may provide a treatment option 
for relapse episodes in children suffering from nicotamide repair enzyme 
deficiencies. Although only reported in a single case, high dose vitamin 
B3 (500 mg/day) in a child with NAXD deficiency improved skin lesions 
and prevented further neurological decline [9]. 
Fig. 1. Blood tests on admission.  
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4. Conclusion 
NAXD deficiency is a multi-system disorder due to the enzymes 
ubiquitous expression. Patients suffering from this condition demon-
strate a range of symptoms in the presence of pyrexia or infection, such 
as neurodegeneration, heart failure or widespread cutaneous lesions. 
The distribution of skin lesions presented in this case were associated 
with areas of relatively high surface temperature such as flexion creases 
and upper back. This may indicate local accumulation of toxic cofactors 
contributing to detachment of the epidermis from dermis. This article 
aims to increase awareness of this rare disease through documentation 
of the associated cutaneous manifestations. These present a diagnostic 
challenge to clinicians emphasising the need for the early identification 
and management of infection in patients with NAXD deficiency. 
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Fig. 2. Figure containing images of Baby X, posterior trunk (A + B) and right axilla (C).  
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